Overall rank by patents
#29,553
Across all tracked assignees
USPTO PatentsView assignee record - 9 granted patents across 17 technology areas, active 2022–2023. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: E21B (EARTH OR ROCK DRILLING; OBTAINING OIL, GAS, WATER, SOLUBLE OR MELTABLE MATERIALS OR A SLURRY OF MINERALS FROM WELLS).
The verdict
NOV holds 9 US patents across 17 technology areas, rank #29,553 of 50,000 tracked assignees.
NOV Canada ULC has been granted 9 US utility patents between 2022 and 2023, placing NOV Canada ULC at rank #29,553 across all assignees tracked by PlainPatent. This portfolio spans 17 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.6 claims per patent with primary concentration in E21B (EARTH OR ROCK DRILLING; OBTAINING OIL, GAS, WATER, SOLUBLE OR MELTABLE MATERIALS OR A SLURRY OF MINERALS FROM WELLS). As a Foreign Corporation, NOV Canada ULC is one of the more focused assignees in the PatentsView dataset. By volume, NOV sits between Nobelpharma Co., Ltd. (9 patents, rank #29,549) and Novogy, Inc. (9 patents, rank #29,557) - the closest US assignees by grant volume. The composite Innovation Score of 51.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2022 through 2023, with 9 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. NOV Canada ULC's 15.6 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 17 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark NOV Canada ULC against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
NOBELPHARMA CO., LTD.
9 patents
NORBROOK LABORATORIES LIMITED
9 patents
NOROTOS, INC.
9 patents
NOSTER INC.
9 patents
NOVARTIS TIERGESUNDHEIT AG
9 patents
NOVATION IQ LLC
9 patents
NOVELIS KOBLENZ GMBH
9 patents
NOVOGY, INC.
9 patents
NOV CANADA ULC
9 patents
What this shows NOV holds 9 patents at rank #29,553, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #29,553 in granted patent volume.
Other assignees with the most granted patents in NOV's primary technology class.
NOV's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
52 Top 11% higher than 89% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2022 | 6 | 66.7% |
| 2023 | 3 | 33.3% |
Top 15 of 17 technology areas
Overall rank by patents
#29,553
Across all tracked assignees
51.9 out of 100
How to use this portfolio
NOV's 9 grants land it in the top 11% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.